#busnines

Read Latest India Business News 8th July 2019:

New Post has been published on https://ocgreenrelief.org/busnines/governor-brown-signed-major-reform-will-protect-californians-asset-forfeiture-abuse

Governor Brown signed a major reform that will protect all Californians from asset forfeiture abuse.

Drug Policy Alliance Ron,

We did it! After months of advocacy from supporters like you, today Governor Brown signed a major reform that will protect all Californians from asset forfeiture abuse.

Senate Bill 443, authored by Senator Holly Mitchell (D-Los Angeles) and Assemblymember David Hadley (R-Torrance), establishes some of the strictest standards to protect due process and property rights by requiring a conviction in most cases before property can be permanently forfeited by law enforcement.

You stuck with us in the fight to get SB 443 through the legislature and signed by Governor Brown. Thank you for making this victory possible!

This bill provides a roadmap for other states to follow in building bipartisan support to protect the property rights of all of who live in the United States.

Reform like SB 443 is of the utmost importance to low income families and immigrant families that do not have the economic resources to fight the federal or state government for return of their hard earned income or property, including cars and home.

Civil asset forfeiture is a remnant of 80’s drug war hysteria that has allowed law enforcement to take and keep someone’s money or property even if the person hasn’t been convicted of a crime, charged, or arrested. It has predominantly harmed innocent, vulnerable people.

Just last year, we released “Above the Law: An Investigation of Civil Asset Forfeiture Abuses in California,” a multi-year report, that took a comprehensive look at asset forfeiture abuses in California. This report kicked off a 2 year campaign that brought reformers of all political stripes together around basic constitutional values – no one should have their property taken by government officials without due process.

Today marks a new direction and we’ve finally reformed this unfair practice in California.

Thank you for leading us to victory!

Sincerely,

Eunisses Hernandez California Policy Associate Drug Policy Alliance

facebook footer.pngtwitter footer.png

You have received this email because [email protected] is a member of the Drug Policy Alliance mailing list.

Unsubscribe from this mailing list. – Contact Us.

New Post has been published on https://www.ocgreenrelief.org/medical-marijuana/experts-discuss-science-med-marijuana

Experts discuss science of med. Marijuana

By Paul Sisson11:30 A.M.JUNE 7, 2014

With San Diego set to grant 36 new permits for medical marijuana dispensaries this year, the drug is about to become more legitimate than ever in the city.

Does that mean cannabis is good medicine?

Only solid science can prove what human ailments the green, leafy plant can truly soothe, but science has never been in the driver’s seat as far as marijuana is concerned.

Californians approved the Compassionate Use Act in 1996, giving doctors broad leeway to prescribe the drug if they determine “that a person’s health would benefit from the use of marijuana in the treatment of cancer, anorexia, AIDS, chronic pain, spasticity, glaucoma, arthritis, migraine or any other illness for which marijuana provides relief.”

While much more is known today about the medical effectiveness of the species cannabis sativa than in 1996, scientists maintain that they can’t prove efficacy for many conditions that marijuana is routinely used to treat. It’s often difficult to distinguish what’s simply promising from what has peer-reviewed scientific legitimacy, researchers said.

Dr. Igor Grant— Bill Wechter

Dr. Igor Grant— Bill Wechter

“There is a complexity here. There isn’t always a right answer,” said Dr. Igor Grant, director of the Center for Medicinal Cannabis Research and chairman of the psychiatry department at UC San Diego.

Public sentiment

Meanwhile, public opinion on marijuana has undergone a dramatic shift nationwide.

In 1996, a Gallup poll showed that only 25 percent of the U.S. population believed marijuana should be legalized. Last year, with Washington state and Colorado approving the drug for recreational use and 21 states allowing at least some sort of marijuana use, Gallup reported that 58 percent of Americans said yes to the following question: “Do you think the use of marijuana should be made legal, or not?”

In this environment, Dr. Robert Blake is left to apply his own philosophy and understanding to the question of who gets a prescription for medical marijuana and who doesn’t.

Blake, a former emergency physician who started doing medical marijuana assessments in 2009, said he writes the bulk of his prescriptions for pain management.

“Most commonly, the person has pain somewhere. It can be physical or emotional,” Blake said.

In the end, he said, cannabis is a good alternative if the patient would otherwise be prescribed narcotics such as Vicodin.

“My experience is that cannabis very effectively reduces the amounts of narcotics that patients are on,” Blake said.

Pain management

Another local authority on the issue of marijuana and pain management is Grant at UC San Diego. The goal of his Medicinal Cannabis Research center, which was created by the California Marijuana Research Act of 1999, has been to delve into this question: What are cannabis’ true medical effects?

Over the years, the center has published some of the most widely cited studies on the effects of marijuana on pain. These studies use the most rigorous scientific controls possible, randomly giving some participants placebos and others marijuana to gauge outcomes.

Most of the clinical trials have looked at chronic nerve pain, the kind usually linked to nerve damage associated with HIV, certain cancer treatments and spinal injuries.

“Neuropathic pain is often caused by nerve damage, and it can produce a burning hypersensitivity that is extremely uncomfortable,” Grant said.

Chronic nerve pain, he added, does not always respond to traditional pain medications. Though the center’s studies on this type of pain were small, with 50 or fewer participants, Grant said the results suggest pretty strongly that marijuana can be an effective alternative.

“I’m pretty confident in saying that cannabis is useful in managing neuropathic pain,” he said.

Alleviating nausea

Medical experts also seem to agree that marijuana helps alleviate nausea.

“With neuropathic pain, I would say that it has an effect, but that effect, and what causes it, is not as clear as it is with nausea,” said Dr. Kari Franson, associate dean of professional education at the University of Colorado’s Skaggs School of Pharmacy.

In addition, researchers said there is plenty of evidence that the drug is an effective appetite stimulant for patients with cancer and HIV. Franson noted, though, that other medications can do a good job of stimulating appetite.

“The reality is, very few people use marijuana for that,” she said.

Studies also support the use of marijuana to control spasticity in multiple sclerosis patients in cases where they may not respond well to other drugs, Grant said.

“Sure, there are other treatments available, but they don’t work with everybody, and not everybody can take enough of those other medications to have an effect,” he said. “Here, cannabis seems to have another (beneficial) role.”

Interest in CBD

The latest marijuana trend focuses on cannabidiol, which most people simply call “CBD,” one of 66 chemical compounds unique to cannabis sativa.

Unlike its cousin tetrahydrocannabinol — usually called THC — cannabidiol does not produce a euphoric high. And some studies indicate that cannabidiol may be useful in controlling seizures, including those that occur frequently in epilepsy patients.

Recently, parents with young children who suffer rare forms of epilepsy that cause debilitating seizures have received significant media attention because they give those kids marijuana extracts with high levels of cannabidiol.

The publicity has made the phone ring a lot at PharmLabs in Ocean Beach, which tests marijuana flowers, leaves and other bits for their levels of THC, CBD and other compounds. PharmLabs’ clients include sellers of medical marijuana.

“We’re constantly getting calls. It’s just ‘CBD, CBD, do you guys test for CBD?’” said PharmLabs co-owner Greg Magdoff.

Greg Magdoff, co-owner of PharmLabs in Ocean Beach, tests a marijuana sample for levels of various chemical compounds like THC and cannabidiol or CBD. — Charlie Neuman

Grant said from the viewpoint of scientific research, there is less evidence for marijuana’s effectiveness against epileptic seizures.

“With epilepsy, there really have not been the level of clinical trials to make me comfortable to say that, ‘Yes, this works,’” he said.

But advocates of medical marijuana have touted in recent years that seizures can be greatly reduced — or even eliminated, according to some anecdotal reports — by dosing with CBD-rich variants of pot.

While he has seen those reports, Grant said the anecdotes simply have not been proven with the full discipline of controlled scientific experiments. “If it helps your child, that’s great, but that doesn’t mean it will help all children,” he said.

Still, Grant said he does not fault parents for trying cannabis extracts on children who get little to no relief from FDA-approved medications for rare forms of epilepsy or other seizure-causing illnesses.

Beyond seizures, Magdoff said people are using marijuana to treat tremors and other symptoms of Parkinson’s disease.

Grant said there is anecdotal evidence that marijuana can help with Parkinson’s, but nothing yet from clinical trials.

Experts discuss Marijuana is also promoted as being able to slow the spread of cancer, treat inflammation, fight fungal infections, aid with sleep and curtail bacterial growth.

None of these uses has been substantiated on a scientific basis, Grant said.

More research

Even ailments for which there is some scientific proof that marijuana is good medicine still need further research, said experts such as Grant and Franson at the University of Colorado. They said the testing should include more participants and be conducted over longer periods of time.

“Much larger clinical trials with much more varied groups of patients are needed,” Grant said. “It’s possible that what is safe and effective in a 30-year-old, for example, may not be in a 70-year-old.”

The aim of offering more comprehensive — and thus more expensive — research is thwarted by the fact that marijuana remains classified as an illegal drug by the federal government.

The federal drug schedule lists cannabis among “Schedule I” drugs such as heroin, LSD, ecstasy and peyote. These substances are defined “as drugs with no currently accepted medical use and a high potential for abuse.”

By comparison, cocaine and methamphetamine are “Schedule II” drugs — considered to have “less abusive potential” than marijuana.

So while San Diego County is home to numerous unlicensed marijuana dispensaries and delivery services, and while state law has allowed residents with valid prescriptions to grow their own pot plants since 1996, scientific researchers must obtain the drug from a single licensed farm at the University of Mississippi.

Grant said getting federal approval to obtain marijuana from that farm takes six to 18 months.

A state bill approved in 1999 provided $8.7 million to fund his center’s studies, but that money has been depleted. Grant said that only one more study — examining marijuana’s effects on people with chronic diabetes — remains to be published.

Colorado frontier

Today, it is Colorado that seems most able to continue research with new clinical trials funded by the excise taxes collected on recreational marijuana sales that started in the state on Jan. 1.

Even then, the federal legality issues make it difficult for Colorado to conduct its own research and stay in good graces with drug czars in Washington, D.C., said Franson at the University of Colorado. She also serves on the governor’s task force that was created to determine how to spend marijuana tax money.

“We are trying to find a way to work with local authorities to move forward, but because we receive federal money, we have to be cautious,” she said.

She also noted that one particularly practical consideration for a state that just legalized marijuana for recreational use is the fact that no one really knows at what point a person consuming marijuana becomes impaired.

Franson, who did research on marijuana in Amsterdam, where drug policies are much more lenient, said it is clear that marijuana impairs coordination, concentration and short-term memory, but that it is unclear how those impairments scale as a person smokes joint after joint.

New Post has been published on http://www.ocgreenrelief.org/medical-marijuana/medical-marijuana-research-hits-wall-u-s-law

Medical Marijuana Research Hits Wall of U.S. Law

Nearly four years ago, Dr. Sue Sisley, a psychiatrist at the University of Arizona, sought federal approval to study marijuana’s effectiveness in treating military veterans with post-traumatic stress disorder. She had no idea how difficult it would be.

The proposal, which has the support of veterans groups, was hung up at several regulatory stages, requiring the research’s private sponsor to resubmit multiple times. After the proposed study received final approval in March from federal health officials, the lone federal supplier of research marijuana said it did not have the strains the study needed and would have to grow more — potentially delaying the project until at least early next year.

Then, in June, the university fired Dr. Sisley, later citing funding and reorganization issues. But Dr. Sisley is convinced the real reason was her outspoken support for marijuana research.

Continue reading the main story RELATED COVERAGE

Dr. Sue Sisley said the University of Arizona had fired her because of her outspoken support for marijuana research. Credit Laura Segall for The New York Times

Dr. Sisley’s case is an extreme example of the obstacles and frustrations scientists face in trying to study the medical uses of marijuana. Dating back to 1999, the Department of Health and Human Services has indicated it does not see much potential for developing marijuana in smoked form into an approved prescription drug. In guidelines issued that year for research on medical marijuana, the agency quoted from an accompanying report that stated, “If there is any future for marijuana as a medicine, it lies in its isolated components, the cannabinoids and their synthetic derivatives.”

Scientists say this position has had a chilling effect on marijuana research.

Though more than one million people are thought to use the drug to treat ailments ranging from cancer to seizures to hepatitis C and chronic pain, there are few rigorous studies showing whether the drug is a fruitful treatment for those or any other conditions.

A major reason is this: The federal government categorizes marijuana as a Schedule 1 drug, the most restrictive of five groups established by the Controlled Substances Act of 1970. Drugs in this category — including heroin, LSD, peyote and Ecstasy — are considered to have no accepted medical use in the United States and a high potential for abuse, and are subject to tight restrictions on scientific study.

Continue reading the main story RELATED IN OPINION

The New York Times Calls for Marijuana LegalizationJULY 26, 2014 video The Marijuana DivideAUG. 2, 2014 Taking Note: Timing the Call to Repeal MarijuanaJULY 28, 2014 Taking Note: The Required White House Response on MarijuanaJULY 29, 2014 In the case of marijuana, those restrictions are even greater than for other controlled substances. (Marijuana remains illegal under federal law, though nearly half the states and the District of Columbia allow its medical use and two, Colorado and Washington, have legalized its recreational use.)

To obtain the drug legally, researchers like Dr. Sisley must apply to the Food and Drug Administration, the Drug Enforcement Administration and the National Institute on Drug Abuse — which, citing a 1961 treaty obligation, administers the only legal source of the drug for federally sanctioned research, at the University of Mississippi. Dr. Sisley’s proposed study also had to undergo an additional layer of review from the Public Health Service that is not required for other controlled substances in such research.

Continue reading the main story The process is so cumbersome that a growing number of elected state officials, medical experts and members of Congress have started calling for loosening the restrictions. In June, a letter signed by 30 members of Congress, including four Republicans, called the extra scrutiny of marijuana projects “unnecessary,” saying that research “has often been hampered by federal barriers.”

“It defies logic in this day and age that marijuana is still in Schedule 1 alongside heroin and LSD when there is so much testimony to what relief medical marijuana can bring,” Gov. Lincoln Chafee of Rhode Island said in an interview. In late 2011, he and the governor of Washington at the time, Christine O. Gregoire, filed a petition asking the federal government to place the drug in a lower category. The petition is still pending with the D.E.A.

Despite the mounting push, there is little evidence that either Congress or the Obama administration will change marijuana’s status soon. In public statements, D.E.A. officials have made their displeasure known about states’ legalizing medical and recreational marijuana.

The agency’s position seems at odds with that of President Obama, whose Justice Department has allowed states to legalize either medical or recreational marijuana as long as they follow certain federal priorities, such as not allowing sales to juveniles. Mr. Obama has also said that he believes marijuana is no more dangerous than alcohol and that he is bothered by the disproportionate number of minorities incarcerated for possession of the drug.

Asked if there was an inconsistency between the president’s stance and that of the Drug Enforcement Administration, a White House spokesman, Matt Lehrich, said: “The administration’s policy continues to be that while the prosecution of drug traffickers remains an important priority, targeting individual marijuana users is not the best allocation of federal law enforcement resources. The D.E.A. is carrying out that policy.”

Photo

Suman Chandra checking marijuana plants at a federal marijuana facility at the University of Mississippi in Oxford. Credit Lance Murphey for The New York Times

Rick Doblin is the founder and director of an organization sponsoring Dr. Sisley’s studies. Credit Gretchen Ertl for The New York Times

There are signs, though, of a possible shift in attitude within the federal government. In May, the D.E.A. issued new rules to increase the government’s production of marijuana for research this year to 650,000 grams from 21,000 grams.

And at the National Institute on Drug Abuse, for instance, records show that at the beginning of this year there were 28 active grants for research into the possible medical benefits of marijuana in six disease categories. Most of the studies focus on the potential therapeutic uses of individual cannabinoid chemicals from marijuana or synthetic versions and not the plant itself. Furthermore, a dozen or so of those studies are being conducted with animals and not humans.

Additionally, other National Institutes of Health entities have been supporting marijuana research. As for independently funded marijuana research, the federal government has cleared 16 projects since 1999, 13 of them at the University of California, San Diego.

Moving the drug to a less restrictive category could do more than reduce some obstacles to research, proponents say. It would be a significant step toward allowing doctors around the country to prescribe the drug. Federal lawmakers say it could also permit medical marijuana operations that are legal at the state level to take business deductions on their federal taxes.

Continue reading the main storyContinue reading the main story Dr. Sisley’s predicament shows that even in states like Arizona, where medical marijuana is legal, the matter remains politically volatile. Last month, Arizona authorized the use of marijuana for patients undergoing conventional treatments for post-traumatic stress disorder. Dr. Sisley’s study is supposed to use five different strains of marijuana that would be smoked or vaporized by 70 veterans. The goal is to develop a marijuana drug, in plant form that would be smoked or vaporized, approved by the Food and Drug Administration.

Her firing seemed to stem from a fight over money. In March, the Arizona House passed a Republican-sponsored bill designed to provide her project with some funding from fees collected in the state’s medical marijuana program. But the measure died when State Senator Kimberly Yee, a Republican who is the chairwoman of the Education Committee, refused to put the legislation on the panel’s agenda. Ms. Yee said at the time that she preferred the funds be used for antidrug education.

Angry about her opposition to the bill, a group of veterans began a recall effort against Ms. Yee. Some of those veterans had been treated by Dr. Sisley in the past, and Senate leaders concluded that Dr. Sisley herself was involved in the campaign.

The State Senate president, Andrew Biggs, called the university’s chief lobbyist, Tim Bee, to complain that Dr. Sisley seemed to be lobbying too aggressively and inappropriately. “Tim said he would call me back after he found out more,” Mr. Biggs said in an interview. “And then he did and told me, ‘This will not be a problem going forward.’ ”

In April, a university vice president, who said he was calling on behalf of the president, Ann Weaver Hart, told Dr. Sisley that Mr. Biggs thought she should resign, Dr. Sisley recounted. In June, she received a letter from the university saying her annual employment contract would not be renewed as of Sept. 26.

Dr. Sisley denied participating in the recall effort. She acknowledged talking to senators and their aides about funding, but as a member of the Arizona Medical Association. “The university could not take the political heat from the hyperconservative legislators and fired me and deserted all these veterans who have been fighting alongside me for years,” she said.

A university spokesman, Chris W. Sigurdson, said that while university policy prevented him from discussing specifics about Dr. Sisley’s case, the school had not been pressured to fire her. (Mr. Biggs also denied trying to get her fired.) He added that the university had proposed that another faculty member take over the project as lead investigator.

Late last month, the university notified Dr. Sisley that it had denied her appeal for reinstatement. Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies, which is sponsoring Dr. Sisley’s research, said he would now try to persuade the Arizona Board of Regents to allow the study to continue at another state institute with Dr. Sisley as the lead investigator.

Mr. Doblin said he was committed to staying with her as the lead investigator and would help her look for an alternate research location. A switch to a new study location would require further regulatory review for the proposed research, which still needs another approval from the D.E.A., Mr. Doblin said.

New Post has been published on http://www.ocgreenrelief.org/medical-marijuana/compound-found-marijuana-shown-turn-cancer

Compound Found In Marijuana Shown To Turn Off Cancer

By Greta McClain Sep 21, 2012 in Health

San Francisco – Researchers at California Pacific Medical Center in San Francisco found that a marijuana compound known as cannabidiol can stop metastasis in many types of aggressive cancers. Sean McAllister, one of the researchers at California Pacific, was studying the effects of Cannabidiol (CDB). Cannabidiol is a non-psychoactive chemical compound in the cannabis plant. Pierre Desprez, a molecular biologist researcher, began studying ID-1, the gene that causes cancer to spread, about 20 years ago. The two combined their research and introduced CDB to cancer cells containing ID-1 in a petri dish. They found that CDB stopped the metastasis of the cancer cells. Metastasis is the spread of disease from one organ or part to another non-adjacent organ or part.

Desprez told the Huffington Post: “What we found was that his Cannabidiol could essentially ‘turn off’ the ID-1. We likely would not have found this on our own. That’s why collaboration is so essential to scientific discovery.”

After their initial study was published in November of last year, the two researchers continued to study the effect of CDB on various cancer cells. Desprez told Yahoo News: “Now we’ve found that Cannabidiol works with many kinds of aggressive cancers — brain, prostate — any kind in which these high levels of ID-1 are present.” High levels of ID-1 have also been found in ovarian, breast, prostate, cervical, liver and endometrial cancers according to the Journal of Experimental and Clinic Cancer Research. A Daily Beast report says Cristina Sanchez, biologist at Complutense University in Madrid, has noticed the effectiveness of THC, the main psychoactive compound in cannabis, on many cancer cells. Harvard University scientists also reported that THC slows tumor growth in common lung cancer. It was McAllister’s research however that found the CDB stopped the spread of the cancer, without the psychoactive side-effects. Examiner.com reports the researchers plan to begin clinical trials on the discovery. Desprez is quoted as saying: “It took us about 20 years of research to figure this out, but we are very excited. “We want to get started with trials as soon as possible.” CBD has already been safely used by people for other ailments. ” Desprez told Yahoo News “We used injections in the animal testing and are also testing pills. “But you could never get enough cannabidiol for it to be effective just from smoking.”

https://www.youtube.com/watch?feature=player_embedded&v=YBuWKiN3fMI

New Post has been published on http://www.ocgreenrelief.org/medical-marijuana/marijuana-users-better-cognitive-skills-study-finds

Marijuana Users Have Better Cognitive Skills, Study Finds

A new study on college students has linked marijuana use with better performance (Cognitive) on certain brain-related tasks.

Despite popular belief, new findings from a team at the University of Minnesota suggest marijuana use at an early age may not be that detrimental to cognitive function.

“Marijuana users were high functioning, demonstrating comparable IQs to controls and relatively better processing speed,” note the researchers.

The study, published March 12 in the Journal of Clinical and Experimental Neuropsychology, found that college students who used marijuana scored better on tests of processing speed and verbal fluency.

The study compared the performance of 35 non-users with 35 daily marijuana users who began using marijuana before the age of 17.

“Marijuana users were high functioning”“Marijuana use during this age span has been most strongly associated with cognitive impairment,” the team writes. All participants were university students between 18-20 years of age, and were told to abstain from using any substances for at least 12 hours before the study.

Interestingly, the two groups showed no significant differences in tests of working memory and verbal learning. However, contrary to their better performance on other tests, marijuana users scored slightly lower on tests of motivated decision making, engagement and verbal memory.

Overall, the team concludes that the study provides “a comprehensive cognitive profile of college-aged daily marijuana users.” But they also warn that the results suggest a few “discrete” impairments associated with marijuana use.

The researchers say more studies should be conducted to pinpoint the underlying factors.

New Post has been published on http://www.ocgreenrelief.org/medical-marijuana/families-celebrate-new-iowa-marijuana-law

Families Celebrate New Iowa Marijuana Law

Since Quinn Stumpf was born, her family has been left with a lot of questions. “We’re finding that there are never any answers,” April Stumpf, Quinn’s mother, said. Quinn suffers hundreds of uncontrollable seizures every day, severely delaying her development. So much so, that she couldn’t join her mother at the State Capitol Friday. “Which is why I’ve got her picture and she’s here in spirit,” Stumpf said. “I know that she’d be smiling if she were here.”

Quinn’s mother was in Des Moines for Governor Branstad’s signing of the Medical Cannabidiol Act into law, which allows families to gain access to a cannabis oil Stumpf says could stop Quinn’s seizures. Branstad said it was stories like Quinn’s that changed his mind on the policy. “I’ve got to say, I was skeptical at first,” Branstad said, noting the similar decision in Utah and Alabama. “I became convinced that this was appropriate public policy for the State of Iowa.” There are some opponents that say legalizing the oil sends the wrong message to would-be illegal users that drug use is acceptable. However, these parents say the oil cannot get you high, so that’s not an issue.

“I wasn’t really sure this day would ever come,” Stumpf said. “It’s a very, very special moment and to share with so many fantastic families we’ve met a long the way in this process is very special and I hold them all dear to my heart.” The new law says a person can possess 32 ounces of the oil with a neurologists supervision, but it must be bought out of State. Still, even thought the Stumpf’s would drive to Colorado several times a year, and spend thousands of dollars, they say it’s worth it to get their daughter back. “She’s just a shell right now and we want to see that personality come back,” Stumpf said. The new law takes effect July 1.

ORIGINAL STORY: Friday marks a milestone for the state of Iowa as Gov. Terry Branstad will sign Senate File 2360, legalizing one form of medical marijuana. While the governor’s signature brings relief to families and epileptic patients, the legislation outlines specific conditions and guidelines. The drug will only be legal in the form of cannabis oil, a non-smoking product of marijuana with low doses of THC, the component that causes a high. Only those with intractable epilepsy will be eligible to use the drug, a type in which the patient does not respond to medication meant to alleviate seizures. Under the law, no other medical conditions will be eligible.

New Post has been published on http://www.ocgreenrelief.org/news/legalize-marijuana-gmo-pot-way-2

Why Legalize Marijuana? Because GMO Pot Is On Its Way

U.S. corporation Monsanto plans to launch production of genetically modified marijuana (GMO), and companies such as Drug Policy Alliance y Open Society Foundation are going to create our own brand, which will be produced under cannabis, information portal La Red 21. Organization of Open Society Foundation is under the control of the shareholder Monsanto, billionaire George Soros. Company Drug Policy Alliance y Open Society Foundation, funded by Monsanto will be responsible for market development of transgenic seeds of marijuana, particularly in Uruguay.

Uruguay – the first country in the world to officially legalize the production and sale of marijuana. Initiator of the law was the leadership of the State, headed by President Jose Mujica. According to authorities, a guarantee of success in Uruguay marijuana legalization should be state regulation of prices for hemp. There are many reasons why Monsanto and other companies producing GMOs would like to learn a new product. Marijuana may be the next major GMO crop. First of all, the company plans to produce GMO manipulate so-called “medical marijuana”. If pharmacists join with GMO companies, pharmaceutical mafia can create transgenic strains with the ability to produce more active compounds which are patented and can be implemented as a medicine.